Lineage Cell Therapeutics Reports Q3 2026 Financial Results and Clinical Updates
Lineage Cell Therapeutics (LCTX) reported third-quarter 2026 results, highlighting a total revenue of $1.5 million, which decreased from the previous year due to lower collaboration revenue from its Roche agreement. Despite the revenue dip, the company maintains a strong liquidity position with $45.2 million in cash and marketable securities, providing a projected operational runway into the second quarter of 2028. The company provided significant clinical updates, including the successful scaling of its AlloSCOPE 5D technology and progress in the REGEN4HD study for Huntington's disease, where six patients have been dosed with no serious adverse events. Additionally, Lineage confirmed the shipment of OpRegen material to Genentech and noted that preclinical animal data for COR1 is expected in early 2027.
Tickers: $RHHBY
Topics: acquisition cash runway clinical trial update revenue decrease